Cost-effectiveness of postremission intensive therapy in patients with acute leukemia
| Autor: | Y. B. Yu, Cheng Hwai Tzeng, Jie Yu You, W. K. Chau, Hueylan Chern, Jyh Pyng Gau, H. C. Hsu, Chao-Hung Ho |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male medicine.medical_specialty Blood transfusion Time Factors Cost effectiveness medicine.medical_treatment Cost-Benefit Analysis Taiwan Kaplan-Meier Estimate Transplantation Autologous Drug Costs Myelogenous Acute lymphocytic leukemia Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Transplantation Homologous Aged Acute leukemia business.industry Hematology Health Care Costs Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Surgery Clinical trial Transplantation Leukemia Leukemia Myeloid Acute Treatment Outcome Oncology Female Arabinonucleosides business Follow-Up Studies Stem Cell Transplantation |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 18(3) |
| ISSN: | 0923-7534 |
| Popis: | Background: We assessed the cost-effectiveness of high-dose arabinoside (HiDAC)-based and allogeneic stem-cell transplantation (alloSCT)-based therapy in patients with acute leukemia. Patients and methods: We analyzed the outcome, cost and cost-effectiveness of 106 patients treated from January 1994 to January 2002 [94 acute myelogenous leukemia (AML)/12 acute lymphoblastic leukemia (ALL)]. Forty-two young patients at either intermediate or unknown cytogenetic risk received postremission intensive therapy (24 HiDAC-based/18 alloSCT-based therapy). Results: After a median follow-up of 50 months, the estimated 7-year overall survival for the HiDAC-based group showed a tendency to be higher than the alloSCT-based group (48% versus 28%, P = 0.1452). The HiDAC-based group spent a significantly lower total cost ($US51 857 versus 75 474, P = 0.004) than the alloSCT-based group. Cost-effectiveness analysis showed that the mean cost per year of life saved for the HiDAC-based group is considerably less expensive than the alloSCT-based group ($US11 224 versus 21 564). The reduced total cost for the HiDAC-based group originated from lower cost in room fees, medication, laboratory and procedure, but not in blood transfusion and professional manpower fees. Conclusion: For the postremission therapy in young AML patients at either intermediate or unknown cytogenetic risk, cost-effectiveness of HiDAC-based therapy compares favorably with that of alloSCT-based therapy, which deserves further clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|